Insulin Modelling Based on Plasma Glucose Measures Via a Minimally-Invasive Glucose Sensor

PreDiabetes Clinical Trial

Official title: Insulin Modelling Based on Plasma Glucose Measures Via a Minimally-Invasive Glucose Sensor

Status Completed

Clinical Trial Summary

The study aims to evaluate insulin as a potential biomarker for prediabetes in Singapore Chinese subjects.

Clinical Trial Description

The prevalence of type 2 diabetes (T2DM) in Singapore is expected to increase from 400,000 to 1,000,000 individuals by 2050, resulting in nearly US$2 billion in economic costs. Pre-diabetes is defined as an intermediate state of hyperglycemia where blood glucose levels are elevated but are below the diagnostic levels of diabetes. In Singapore, approximately 1 in 7, or 430,000 residents are estimated to be pre-diabetic, and globally this number is estimated at 7.3% of adults (equivalent to 352.1 million individuals). Up to 70% of pre-diabetics eventually develop overt T2DM; however, pre-diabetes may be reversible with early detection, providing a window for opportune disease interception.

While blood glucose is currently used to detect pre-diabetes, homeostatic mechanisms can maintain normal blood glucose levels and mask the detection of pre-diabetes until overt hyperglycemia is exhibited. In contrast, numerous studies have demonstrated that insulin levels increase markedly in pre-diabetes, even as marginal changes are observed in glucose levels. In this study, the investigator aims to determine if dynamic insulin levels observed during an oral glucose tolerance test are more sensitive than glucose alone in detecting prediabetes in a Singapore Chinese population. ;

Related Conditions & MeSH terms

• PreDiabetes
• Prediabetic State

• NCT number: NCT06119035
• Study type: Interventional
• Source: Clinical Nutrition Research Centre, Singapore
• Status: Completed
• Phase: N/A
• Start date: November 6, 2023
• Completion date: January 12, 2024